Milan, Italy (May 22, 2023)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its granting of the patent No. 18780237.6 in Europe by the European Patent Office.

The patent application No. 18780237.6 is referred to the first family of patents, already granted in Italy. The granting of this patent represents a fundamental milestone for the company and strengthens one of the main corporate assets in order to promote and develop innovative drug-delivery technology in the field of ophthalmology.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.